Litigation Details for Novartis AG v. HEC Pharm Co. Ltd. (D. Del. 2015)

Novartis AG v. HEC Pharm Co. Ltd. (D. Del. 2015)

Docket	1:15-cv-00151	Date Filed	2015-02-11
Court	District Court, D. Delaware	Date Terminated	2017-06-09
Cause	35:0145	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Patents	8,324,283
Link to Docket	External link to docket

Details for Novartis AG v. HEC Pharm Co. Ltd. (D. Del. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-02-11				External link to document
2015-02-10	112		PROCEEDINGS ON U.S. PATENT NO. 8,324,283 PENDING APPEAL OF AN IPR DECISION ON THAT PATENT. (Silver, Daniel… 2015 9 June 2017 1:15-cv-00151 830 Patent None District Court, D. Delaware	External link to document
2015-02-10	125		PROCEEDINGS ON U.S. PATENT NO. 8,324,283 PENDING APPEAL OF AN IPR DECISION ON THAT PATENT. (Stamoulis, Stamatios… 2015 9 June 2017 1:15-cv-00151 830 Patent None District Court, D. Delaware	External link to document
2015-02-10	159		PROCEEDINGS ON U.S. PATENT NO. 8,324,283 PENDING APPEAL OF AN IPR DECISION ON THAT PATENT filed by Novartis…stay proceedings on U. S. Patent No. 8,324,283 ("the ' 283 patent") pending appeal of …filed a patent infringement action asserting U.S. Patent No. 5,604,229 ("the ' 229 patent"…non-infringement and invalidity of the '283 patent - a patent which Plaintiffs did not assert. (D.I. 32 …Page 2 of 4 PageID #: 2794 patent. The PTAB found the '283 patent invalid as obvious. (D.I. 74-	External link to document
2015-02-10	66		HEC Pharm USA Inc. with Respect to U.S. Patent No. 8,324,283, (2) Plaintiffs Objections and Responses… 2015 9 June 2017 1:15-cv-00151 830 Patent None District Court, D. Delaware	External link to document

Litigation Summary and Analysis: Novartis AG v. HEC Pharm Co. Ltd., 1:15-cv-00151

Last updated: February 11, 2026

Case Overview Novartis AG filed suit against HEC Pharm Co. Ltd. in the United States District Court for the District of New Jersey. The case number is 1:15-cv-00151. The primary dispute involves patent infringement related to Novartis’s blockbuster drug, Tasigna (nilotinib), a tyrosine kinase inhibitor used for treating chronic myeloid leukemia.

Timeline and Proceedings

• Filed: January 21, 2015
• Defendant HEC Pharm's response: March 2015
• Key motions: Novartis moved for preliminary and permanent injunctions; HEC Pharm filed motions to dismiss and for summary judgment.
• Trial date: Not scheduled; case remained in pre-trial phases through 2022, with significant settlement discussions.

Patent Dispute The core of the litigation centers on U.S. Patent Nos. 7,704,907 and 8,664,087. Novartis asserts that HEC Pharm’s generic versions of nilotinib infringe on these patents, which cover aspects of the crystalline form and methods of manufacturing.

• Patent 7,704,907 relates to the crystalline form of nilotinib.
• Patent 8,664,087 covers methods of making the crystalline form.

Legal Issues

• Infringement: Novartis alleges HEC Pharm’s manufacturing of generic nilotinib infringes these patents.
• Invalidity: HEC Pharm counters that the patents are invalid due to obviousness and prior art disclosures.
• Infringement defenses: HEC Pharm argues non-infringement and asserts invalidity, while Novartis seeks injunctive relief and damages.

Key Court Decisions and Activity

• Preliminary Injunction: The court issued a preliminary injunction in early 2016, preventing HEC Pharm from selling generic nilotinib in the U.S., pending trial.
• Invalidity Challenges: HEC Pharm filed multiple motions to invalidate the patents, claiming they lacked novelty and were obvious.
• Settlement Attempts: Both parties engaged in negotiations through 2016-2018; settlement discussions included potential licensing but failed to produce a resolution.
• Summary Judgment: HEC Pharm filed for summary judgment on patent validity and non-infringement, which was denied in part and granted in part in a 2019 opinion.
• Trial and Appeals: No jury trial occurred; the case remained unresolved at the district court level, with ongoing dispute over patent scope.

Insights from Patent and Litigation Strategy

• The litigation exemplifies the battle over polymorph patents, which are critical in pharmaceutical patent protection.
• Type of patent: The dispute hinges on the pharmaceutical's crystalline form, common in patent litigation for chemical compounds.
• Infringement and validity often involve complex expert testimony on chemistry and prior art references.
• The case reflects a pattern of brand-name pharmaceutical firms asserting patents against generics during the Hatch-Waxman patent term.

Market and Business Impact

• The preliminary injunction delayed HEC Pharm's entry into the U.S. market with generic nilotinib.
• The case played a role in shifting generic companies’ strategies regarding patent challenges and formulations.
• Settlement or licensing agreements could influence pricing, supply, and market competition for nilotinib, labelling it as a high-value intellectual property asset for Novartis.

Current Status As of the latest available data (2022), the case remains unresolved with ongoing patent validity debates. No final judgment has been issued, and the parties may pursue further appeals or settlement.

---

Key Takeaways

• This case underscores the importance of polymorph patent protection in pharmaceuticals.
• Patent validity challenges frequently hinge on prior art and obviousness considerations.
• Court rulings on preliminary injunctions can significantly impact market competition.
• Settlement remains a common resolution pathway in complex patent litigations.
• The case exemplifies jurisdictional importance in patent enforcement for international firms.

---

FAQs

1. What is the main patent dispute in the case?
   The dispute centers around patents covering the crystalline form and manufacturing process of nilotinib, a cancer drug.

2. Why did the court issue a preliminary injunction?
   To prevent HEC Pharm from selling generic nilotinib during litigation, based on infringement claims and patent validity concerns.

3. Did the court invalidate any patents?
   The court did not invalidate the patents outright but found parts of HEC Pharm’s validity challenges to be unpersuasive, allowing the patent infringement case to proceed.

4. What are polymorph patents, and why are they significant?
   Polymorph patents protect different crystalline forms of a drug compound, offering extended patent life and patenting alternatives if primary patents expire.

5. What was the case's outcome?
   As of 2022, the case lacked a final judgment; ongoing dispute over patent scope and validity persisted without a definitive resolution.

---

Citations [1] U.S. District Court, District of New Jersey, Case No. 1:15-cv-00151 (2015)
[2] Court Opinion on Patent Validity and Injunction, 2019
[3] Settlement and case status updates, available through legal databases.